BroadcastMed introduces content marketing platform for pharmaceutical, biotechnology organizations

BroadcastMed, Inc. a digital medical broadcaster and leading provider of cloud based physician education portals introduces its content marketing platform tailored to pharmaceutical and biotechnology organizations. The Platform offers a comprehensive suite of video, social and mobile tools to both publish and distribute content and engage physician members at over 16 specialty and condition specific syndication channels.

The BroadcastMed Network is a trusted resource for an established community of engaged medical professionals. The content is curated by the country's finest academic medical centers, device manufacturers and medical education companies. "Having instant access to trustworthy clinical news, emerging clinical information and educational content is invaluable to physicians." says Ross Joel, CEO and Co-Founder of BroadcastMed, Inc. "While adding pharma and biotech content clearly is beneficial our physician community, what's in it for our clients is an extension of their reach." Joel added.

Source: BroadcastMed, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.

or

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Atypical mutation offers clues to personalized pancreatic cancer treatment